Rigel Pharmaceuticals Inc (RIGL): Net Income
$367.02M
Year ended 2025-12-31
$321.91M
Trailing 12 months to 2026-06-30
| Period ended | Net Income | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $367.02M | n/m | 2026-03-03, From 2025-01-01 |
| 2024-12-31 | $17.48M | n/m | 2026-03-03, From 2024-01-01 |
| 2023-12-31 | -$25.09M | n/m | 2026-03-03, From 2023-01-01 |
| 2022-12-31 | -$58.57M | n/m | 2025-03-04, From 2022-01-01 |
| 2021-12-31 | -$17.91M | n/m | 2024-03-05, From 2021-01-01 |
| 2020-12-31 | -$29.74M | n/m | 2023-03-07, From 2020-01-01 |
| 2019-12-31 | -$66.89M | n/m | 2022-03-01, From 2019-01-01 |
| 2018-12-31 | -$70.48M | n/m | 2021-03-02, From 2018-01-01 |
| 2017-12-31 | -$77.99M | n/m | 2020-02-27, From 2017-01-01 |
| 2016-12-31 | -$69.22M | n/m | 2019-02-28, From 2016-01-01 |
| 2015-12-31 | -$51.46M | n/a | 2018-03-06, From 2015-01-01 |
Net Income at similar companies
| Company | Year ended | Net Income | Change YoY |
|---|---|---|---|
| Rigel Pharmaceuticals Inc (RIGL) | 2025-12-31 | $367.02M | n/m |
| Rapport Therapeutics, Inc. (RAPP) | 2025-12-31 | -$111.48M | n/m |
| Ardelyx, Inc. (ARDX) | 2025-12-31 | -$61.60M | n/m |
| Syndax Pharmaceuticals Inc (SNDX) | 2025-12-31 | -$285.42M | n/m |
| Dianthus Therapeutics, Inc. (DNTH) | 2025-12-31 | -$162.34M | n/m |
| Olema Pharmaceuticals, Inc. (OLMA) | 2025-12-31 | -$162.45M | n/m |
| Vanda Pharmaceuticals Inc. (VNDA) | 2025-12-31 | -$220.47M | n/m |
| Oruka Therapeutics, Inc. (ORKA) | 2025-12-31 | -$105.43M | n/a |
| Rhythm Pharmaceuticals, Inc. (RYTM) | 2025-12-31 | -$196.54M | n/m |
Compare RIGL, RAPP, ARDX, SNDX side by side · Screen every company in Pharmaceutical Preparations ↗